KR20110005862A - 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도 - Google Patents

변형된 제ｉｘ인자 폴리펩티드 및 이의 용도 Download PDF

Info

Publication number
KR20110005862A
KR20110005862A KR1020107025567A KR20107025567A KR20110005862A KR 20110005862 A KR20110005862 A KR 20110005862A KR 1020107025567 A KR1020107025567 A KR 1020107025567A KR 20107025567 A KR20107025567 A KR 20107025567A KR 20110005862 A KR20110005862 A KR 20110005862A
Authority
KR
South Korea
Prior art keywords
polypeptide
fix
amino acid
glu
polypeptides
Prior art date
Application number
KR1020107025567A
Other languages
English (en)
Korean (ko)
Inventor
앨런 브룩스
존 이. 머피
마리안 세토
샤오챠오 지앙
찬드라 파텔
우베 그리찬
코르넬리아 키르흐너
울리히 하우프츠
Original Assignee
바이엘 헬스케어 엘엘씨
바이엘 쉐링 파마 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 헬스케어 엘엘씨, 바이엘 쉐링 파마 악티엔게젤샤프트 filed Critical 바이엘 헬스케어 엘엘씨
Publication of KR20110005862A publication Critical patent/KR20110005862A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020107025567A 2008-04-16 2009-04-16 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도 KR20110005862A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12456708P 2008-04-16 2008-04-16
US61/124,567 2008-04-16
US4596108P 2008-04-17 2008-04-17
US61/045,961 2008-04-17

Publications (1)

Publication Number Publication Date
KR20110005862A true KR20110005862A (ko) 2011-01-19

Family

ID=41265284

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107025567A KR20110005862A (ko) 2008-04-16 2009-04-16 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도

Country Status (17)

Country Link
EP (1) EP2288622A4 (fr)
JP (1) JP2011517951A (fr)
KR (1) KR20110005862A (fr)
CN (1) CN102083856A (fr)
AU (1) AU2009244633A1 (fr)
BR (1) BRPI0910702A2 (fr)
CA (1) CA2721683A1 (fr)
CO (1) CO6311000A2 (fr)
CR (1) CR11737A (fr)
DO (1) DOP2010000311A (fr)
EC (1) ECSP10010551A (fr)
IL (1) IL208718A0 (fr)
MX (1) MX2010011345A (fr)
RU (1) RU2010146387A (fr)
SG (1) SG189790A1 (fr)
SV (1) SV2010003704A (fr)
WO (1) WO2009137254A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2423307A1 (fr) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Polypeptides du facteur IV à coagulation modifiée et leur utilisation pour le traitement
WO2009051717A2 (fr) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Variantes du facteur ix humain qui présentent une demi-vie prolongée
TR201813067T4 (tr) 2008-09-15 2018-09-21 Uniqure Biopharma B V Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem.
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
AU2013204511B2 (en) * 2010-11-03 2016-03-17 Gc Biopharma Corp. Modified factor ix polypeptides and uses thereof
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
PL2717898T3 (pl) 2011-06-10 2019-06-28 Bioverativ Therapeutics Inc. Związki o działaniu prokoagulacyjnym i sposoby ich stosowania
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
JP5967631B2 (ja) * 2012-04-27 2016-08-10 学校法人日本大学 上皮及び内皮損傷の治療剤
EP2877202A4 (fr) 2012-07-25 2016-06-01 Biogen Ma Inc Essai de surveillance de facteur sanguin et utilisations de celui-ci
TWI810729B (zh) 2012-09-25 2023-08-01 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
EP2908847B1 (fr) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Procédés d'utilisation d'une dose fixe d'un facteur de coagulation
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
ES2959747T3 (es) 2013-02-15 2024-02-28 Bioverativ Therapeutics Inc Gen del factor VIII optimizado
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
EP3065769A4 (fr) 2013-11-08 2017-05-31 Biogen MA Inc. Composé de fusion procoagulant
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
WO2015095809A1 (fr) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Utilisation de cultures de semences sous perfusion pour améliorer la capacité de production en alimentation programmée de produits biopharmaceutiques et la qualité des produits
MX2016012447A (es) 2014-03-24 2017-01-06 Biogen Ma Inc Formulaciones de factor ix liofilizadas.
EP3160478A4 (fr) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Gène du facteur ix optimisé
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
LT3411478T (lt) 2016-02-01 2022-09-26 Bioverativ Therapeutics Inc. Optimizuoti viii faktoriaus genai
CN105695616A (zh) * 2016-04-22 2016-06-22 王冬国 诊断甲状腺癌的分析标志物及其应用
BR112019011115A2 (pt) 2016-12-02 2019-10-01 Bioverativ Therapeutics Inc métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos
AU2018215092A1 (en) 2017-01-31 2019-08-29 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
FR3069540B1 (fr) 2017-07-28 2019-09-13 Universite Claude Bernard Lyon 1 Proteine modifiee avec demi-vie amelioree
TW201920255A (zh) 2017-08-09 2019-06-01 美商生物化學醫療公司 核酸分子及其用途
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
JP2020534837A (ja) 2017-09-27 2020-12-03 シギロン セラピューティクス， インコーポレイテッドＳｉｇｉｌｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 活性細胞を含む方法、組成物、及び移植可能な要素
IL312315A (en) 2018-04-04 2024-06-01 Sigilon Therapeutics Inc Implantable particles and related methods
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2020086408A1 (fr) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bioprocédé d'expression génique transitoire basé sur une perfusion à haut rendement
KR20220009389A (ko) 2019-04-17 2022-01-24 코디악 바이오사이언시즈, 인크. 엑소좀 및 aav 의 조성물
WO2021154414A2 (fr) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Thérapie génique pour l'hémophilie b avec un vecteur de capside d'aav chimérique codant pour des polypeptides du facteur ix modifiés
EP4298737A1 (fr) * 2021-02-24 2024-01-03 BlueHalo LLC Système et procédé d'alimentation de réseau à commande de phase à formation de faisceau numérique
WO2024081310A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie
WO2024081309A1 (fr) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Cellules modifiées et éléments implantables pour le traitement d'une maladie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
WO1999003496A1 (fr) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Facteur ix antihemophilique presentant une activite de coagulation augmentee
HUP0401534A3 (en) * 2001-09-04 2006-01-30 Merck Patent Gmbh Modified factor ix
US20050008580A1 (en) * 2003-04-09 2005-01-13 Wyeth Hemophilia treatment by inhalation of coagulation factors
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP2423307A1 (fr) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Polypeptides du facteur IV à coagulation modifiée et leur utilisation pour le traitement
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
CN102083856A (zh) 2011-06-01
SG189790A1 (en) 2013-05-31
JP2011517951A (ja) 2011-06-23
WO2009137254A2 (fr) 2009-11-12
SV2010003704A (es) 2011-02-21
CR11737A (es) 2011-02-07
WO2009137254A3 (fr) 2010-01-14
DOP2010000311A (es) 2011-02-28
EP2288622A2 (fr) 2011-03-02
CA2721683A1 (fr) 2009-11-12
ECSP10010551A (es) 2010-11-30
AU2009244633A1 (en) 2009-11-12
CO6311000A2 (es) 2011-08-22
RU2010146387A (ru) 2012-05-27
MX2010011345A (es) 2011-02-23
IL208718A0 (en) 2010-12-30
EP2288622A4 (fr) 2012-04-18
BRPI0910702A2 (pt) 2016-07-05

Similar Documents

Publication Publication Date Title
KR20110005862A (ko) 변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
TWI595004B (zh) 經修飾之第九因子多胜肽及其用途
JP5659312B1 (ja) 改変された第ｖｉｉ因子ポリペプチドおよびその使用
ES2704083T3 (es) Polipéptidos de factor x modificados y usos de los mismos
EP1991255B1 (fr) Polypeptides du facteur de coagulation x avec des propriétés d'activation modifiées
EP3222287A1 (fr) Compositions de facteur ix de coagulation et procédés de fabrication et d'utilisation
EP2108045B1 (fr) Protéines mutantes de fix améliorées destinées à traiter l'hémophilie b
EP1728798A1 (fr) Polypeptides du facteur X de la coagulation avec propiertés d'activation modifiées
KR20110015551A (ko) 제ｉｘ인자의 부위-지정 변형
SG178119A1 (en) Modified factor ix polypeptides and uses thereof
EP2108046B1 (fr) Protéines mutantes de fix fviii-indépendantes destinées au traitement de l'hémophilie a
US20120178693A1 (en) Cofactors for Thrombin Activation of Factor VII and Uses Thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application